DOCU Form 144: Proposed Sale of 728 Shares Valued $58,458
Form 144 filed for DOCU discloses a proposed sale of 728 shares of DocuSign common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $58,458.40.
Rhea-AI Filing Summary
Form 144 filed for DOCU discloses a proposed sale of 728 shares of DocuSign common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $58,458.40. The filing lists the approximate date of sale as 09/15/2025 and reports total shares outstanding as 201,104,117. The shares were acquired as restricted stock from the issuer on 08/29/2025 (365 shares) and 09/04/2025 (363 shares), with payment recorded on those same dates. The filer attests they have no undisclosed material information and certifies the accuracy of the notice.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider sale notice of a small number of restricted shares; compliance disclosure appears complete.
The Form 144 documents a planned sale of 728 restricted shares by a person who acquired the shares from the issuer on 08/29/2025 and 09/04/2025. The broker is Morgan Stanley Smith Barney LLC and the intended sale date is 09/15/2025. The aggregate market value reported is $58,458.40 against reported outstanding shares of 201,104,117, indicating the transaction is immaterial to total capitalization. From a compliance perspective, the filing includes required acquisition dates, nature of acquisition, broker details, and the seller's representation regarding material nonpublic information, which are the primary elements regulators review for Rule 144 notices.
TL;DR: Transaction size is negligible versus outstanding shares; unlikely to move market or signal major insider change.
The sale totals 728 shares acquired as restricted stock, split between two close acquisition dates. With an aggregate value of $58,458.40 relative to 201,104,117 shares outstanding, this disposal represents a de minimis percentage of float. There are no reported securities sold in the prior three months, and no indication of nonroutine conditions. For investors, this filing signals standard post-vesting or post-grant liquidity rather than a material transfer affecting ownership control or company valuation.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does DOCU Form 144 report?
Does the filing indicate material undisclosed information?
Who is the broker handling the proposed sale?
Were any other securities of the issuer sold by this person in the past three months?
AI-generated analysis. How Rhea-AI works. Not financial advice.